

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 June 2002 (20.06.2002)

PCT

(10) International Publication Number
WO 02/47687 A1

(51) International Patent Classification⁷: **A61K 31/47**

(21) International Application Number: PCT/US01/47451

(22) International Filing Date: 5 December 2001 (05.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/254,600 11 December 2000 (11.12.2000) US

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, Philadelphia, PA 19103
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DHANAK,**
Dashyant [GB/US]; 709 Swedeland Road, King of
Prussia, PA 19406 (US). **KNIGHT, Steven, D.** [US/US];
709 Swedeland Road, King of Prussia, PA 19406 (US).

(74) Agents: **HALL, Linda, E.** et al.; SmithKline Beecham
Corporation, Corporate Intellectual Property, UW2220,
709 Swedeland Road, P.O. Box 1539, King of Prussia, PA
19406-0939 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/47687 A1

(54) Title: UROTENSIN-II RECEPTOR ANTAGONISTS

(57) Abstract: The present invention relates to a method of antagonizing the Urotensin-II receptor by 2-(NH-substituted) quinolones.

UROTENSIN-II RECEPTOR ANTAGONISTS

FIELD OF THE INVENTION

The present invention relates generally to a method of antagonizing the Urotensin-II
5 receptor by 2-(NH- substituted) quinolones.

BACKGROUND OF THE INVENTION

The integrated control of cardiovascular homeostasis is achieved through a
combination of both direct neuronal control and systemic neurohormonal activation.
10 Although the resultant release of both contractile and relaxant factors is normally under
stringent regulation, an aberration in this *status quo* can result in cardiohemodynamic
dysfunction with pathological consequences.

The principal mammalian vasoactive factors that comprise this neurohumoral axis,
namely angiotensin-II, endothelin-1, norepinephrine, all function via an interaction with
15 specific G-protein coupled receptors (GPCR). Urotensin-II, represents a novel member of
this neurohumoral axis.

In the fish, this peptide has significant hemodynamic and endocrine actions in
diverse end-organ systems and tissues:

- smooth muscle contraction
20 both vascular and non-vascular in origin including smooth muscle preparations from
the gastrointestinal tract and genitourinary tract. Both pressor and depressor activity
has been described upon systemic administration of exogenous peptide
- osmoregulation:
effects which include the modulation of transepithelial ion (Na^+ , Cl^-) transport.
25 Although a diuretic effect has been described, such an effect is postulated to be
secondary to direct renovascular effects (elevated GFR)
- metabolism:
urotensin-II influences prolactin secretion and exhibits a lipolytic effect in fish
(activating triacylglycerol lipase resulting in the mobilization of non-esterified free
30 fatty acids)
(Pearson, *et. al. Proc. Natl. Acad. Sci. (U.S.A.)* 1980, 77, 5021; Conlon, *et. al. J.*
Exp. Zool. 1996, 275, 226.)

In studies with human Urotensin-II it was found that it:

- was an extremely potent and efficacious vasoconstrictor

- exhibited sustained contractile activity that was extremely resistant to wash out
- had detrimental effects on cardiac performance (myocardial contractility)

Human Urotensin-II was assessed for contractile activity in the rat-isolated aorta and was shown to be the most potent contractile agonist identified to date. Based on the *in vitro* pharmacology and *in vivo* hemodynamic profile of human Urotensin-II it plays a pathological role in cardiovascular diseases characterized by excessive or abnormal vasoconstriction and myocardial dysfunction. (Ames *et. al. Nature* 1999, 401, 282)

Compounds that antagonize the Urotensin-II receptor may be useful in the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, restenosis, asthma, (Hay DWP, Luttmann MA, Douglas SA: 2000, Br J Pharmacol: In press.) neurogenic inflammation and metabolic vasculopathies all of which are characterized by abnormal vasoconstriction and/or myocardial dysfunction. Since U-II and GPR14 are both expressed within the mammalian CNS (Ames *et. al. Nature* 1999, 401, 282), they also may be useful in the treatment of addiction, schizophrenia, impulsivity, anxiety, stress, depression, and neuromuscular function. Functional U-II receptors are expressed in rhabdomyosarcomas cell lines and therefore may have oncological indications. Urotensin may also be implicated in various metabolic diseases such as diabetes (Ames *et. al. Nature* 1999, 401, 282, Nothacker *et al., Nature Cell Biology* 1: 383-385, 1999)

SUMMARY OF THE INVENTION

In one aspect this invention provides for the use of 2-(NH-substituted) quinolones for antagonizing the Urotensin-II receptor and thereby treating conditions associated with Urotensin-II imbalance.

In a second aspect, this invention provides for the use of 2-(NH-substituted) quinolones for the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, restenosis, asthma, neurogenic inflammation and metabolic vasculopathies, addiction, schizophrenia, impulsivity, anxiety, stress, depression, neuromuscular function, and diabetes.

The urotensin antagonist may be administered alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors,


vasopeptidase inhibitors, diuretics, digoxin, and dual non-selective β -adrenoceptor and α_1 -adrenoceptor antagonists.

Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

5

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides for a method of treating conditions associated with Urotensin-II imbalance by antagonizing the Urotensin-II receptor which comprises administering to a patient in need thereof, a compound of Formula I:



10

(I)

wherein:

R_1 is phenyl, thienyl, benzothienyl, benzhydryl, xanthenyl, naphthyl, or indolyl, all of which may be substituted or unsubstituted by one or two substituents selected from: halogens, -CN, CH_3CO -, (C_{1-6}) alkyl, mono to perfluoro (C_{1-3}) alkyl, (C_{2-6}) alkenyl, (C_{1-6}) alkoxy, (C_{5-10}) aryloxy, phenyl (C_{1-6}) alkoxy, -OH, - NH_2 , mono- or di- (C_{1-6}) alkylamino, - NO_2 , - CO_2H , - $\text{CO}_2(\text{C}_{1-6})$ alkyl, - $\text{S}(\text{C}_{1-6})$ alkyl, - $\text{SO}_2(\text{C}_{1-6})$ alkyl, H_2NSO_2 -, - CONH_2 , - $\text{SO}_2(\text{C}_{5-10})$ aryl, or - $\text{CO}_2\text{N}\{(\text{C}_{1-6})\text{alkyl}\}_2$;

15

R_2 is hydrogen or Me;

20

R_3 is hydrogen, I, F, Br, Cl, C_{1-6} alkyl, C_{1-6} alkoxy, -OH, or -CN;

X is - $\text{CH}(\text{R}_4)$ - or CO;

R_4 is hydrogen, $\text{C}\Theta$, C_{1-6} alkyl, or phenyl;

Y is - $\text{CH}_2\text{C}(\text{R}_5)(\text{R}_6)\text{CH}_2$ -;

R_5 and R_6 are independently hydrogen or C_{1-6} alkyl;

25

or a pharmaceutically acceptable salt thereof.

Methods for preparing compounds of Formula I can be found in co-pending PCT application PCT/EP99/02648 which is incorporated by reference herein.

When used herein, the term "alkyl" and similar terms such as "alkoxy" includes all straight chain and branched isomers. Representative examples thereof include methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl, *t*-butyl, *n*-pentyl and *n*-hexyl.

When used herein, the terms 'halogen' and 'halo' include fluorine, chlorine, bromine and iodine and fluoro, chloro, bromo and iodo, respectively.

By the term "aryl" as used herein, unless otherwise defined, is meant cyclic or polycyclic aromatic C₅-C₁₂ ring. Examples are phenyl and naphthyl.

The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active form. All of these compounds and their diastereoisomers are contemplated to be within the scope of the present invention.

Preferably R₁ is substituted phenyl, thienyl, benzothienyl, benzhydryl, or indolyl. More preferably R₁ is 1-benzyl-3-indolyl, 4,6-dichloro-2-indolyl, 3-trifluoromethylthiophenyl, 2-fluoro-5-trifluoromethylphenyl, 4,6-dichloro-3-methyl-2-indolyl, 6-methoxy-4-trifluoromethyl-2-indolyl, or 3,4-dichlorophenyl, 3,5-dibromophenyl or 4-chloro-3-trifluoromethylbenzyl.

Preferably R₂ is hydrogen;

Preferably R₃ is hydrogen, halo, or alkyl; more preferably R₃ is hydrogen, Cl, or Me.

Preferably X is CH₂.

Preferably Y is CH₂CR₅R₆CH₂, where R₅, and R₆ are hydrogen, dimethyl, or forms a cyclic C₍₅₋₆₎ tether; or R₅ is hydrogen; and R₆ is *n*-propyl, phenyl, benzyl, or methyl. More preferably Y is CH₂CR₅R₆CH₂, wherein R₅, and R₆ are H; or R₅ is hydrogen and R₆ is *n*-propyl, or phenyl.

Preferred Compounds are:

2-{2-[(1-Benzyl-3-indolylmethylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;

2-{2-[(3-Trifluoromethylthiobenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;

2-{2-[(2-Fluoro-5-trifluoromethylbenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;

2-{2-[(4-*n*-Butylbenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;

2-{2-[(2,5-Dimethyl-1-phenyl-3-pyrrolylmethylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;

2-{2-[(1-Bromo-2-naphthylmethylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;

2-{2-[(4-Bromo-3,5-dimethoxybenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;

2-{2-[(5-Bromo-2-fluorobenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one

- 2-{2-[(3-Iodobenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
 2-{2-[(2,3-Difluoromethylenedioxybenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
 2-{2-[(3-Fluoro-4-trifluoromethylbenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
 5 2-{2-[(4,5-Dibromo-2-thienylmethylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
 2-{2-[(2-Fluorenylmethylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
 2-{2-[(3-Indolylmethylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
 2-{2-[(1-Acetyl-3-indolylmethylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
 2-{2-[(2-Chloro-3-trifluoromethylbenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
 10 2-{2-[(2-Chloro-5-trifluoromethylbenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
 2-{2-[(3,4-Dichlorobenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
 2-{2-[(3,5-bis-Trifluoromethylbenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
 2-{2-[(3,5-Dimethylbenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
 2-[3-(4,6-Dichloro-2-indolylmethylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
 15 2-[3-(4,6-Dichloro-3-methyl-2-indolylmethylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
 2-[3-(6-Methoxy-4-trifluoromethyl-2-indolylmethylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
 2-[3-(3-Trifluoromethylthiobenzylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
 2-[3-(3,4-Dichlorobenzylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
 20 2-[3-(3,5-Dibromobenzylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
 2-[3-(4,6-Dimethyl-2-indolylmethylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
 2-[3-(3,4-Dichlorobenzylamino)prop-1-ylamino]-6-methyl-1*H*-quinolin-4-one;
 2-[3-(4,6-bis-Trifluoromethyl-2-indolylmethylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
 2-[3-(3-Chlorobenzylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
 25 2-[3-(4,5-Dibromo-2-thienylmethylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
 2-[3-(3,4-Difluorobenzylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
 2-[3-(1-Benzyl-3-indolylmethylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
 2-[3-(2-Fluoro-5-trifluoromethylbenzylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
 2-{3-[(1-Benzyl-1*H*-indol-3-ylmethyl)-amino]-2-methyl-propylamino}-1*H*-quinolin-4-one;
 30 2-{2-[(3-Phenoxy-benzylamino)-methyl]-pentylamino}-1*H*-quinolin-4-one;
 2-{3-[(9*H*-Xanthen-9-ylmethyl)-amino]-propylamino}-1*H*-quinolin-4-one;
 2-{3-[(1-Benzenesulfonyl-1*H*-indol-3-ylmethyl)-amino]-propylamino}-1*H*-quinolin-4-one;
 2-(3-{[1-(1-Phenyl-methanoyl)-1*H*-indol-3-ylmethyl]-amino}-propylamino)-1*H*-quinolin-4-one;

- 2-{3-[(4-Bromo-5-ethyl-thiophen-2-ylmethyl)-amino]-propylamino}-1*H*-quinolin-4-one;
 2-{3-[(6-Bromo-benzo[*b*]thiophen-2-ylmethyl)-amino]-propylamino}-1*H*-quinolin-4-one;
 2-{3-[(4-Bromo-thiophen-2-ylmethyl)-amino]-propylamino}-1*H*-quinolin-4-one;
 2-[3-(3,5-Dichloro-benzylamino)-propylamino]-1*H*-quinolin-4-one;
 5 2-[3-(3-Iodo-benzylamino)-propylamino]-1*H*-quinolin-4-one;
 2-[3-(4-Butyl-benzylamino)-propylamino]-1*H*-quinolin-4-one;
 2-[3-(4-Chloro-3-trifluoromethyl-benzylamino)-propylamino]-1*H*-quinolin-4-one;
 2-{2-[(2-Fluoro-4-trifluoromethyl-benzylamino)-methyl]-pentylamino}-1*H*-quinolin-4-one;
 2-{2-[(4-Chloro-3-trifluoromethyl-benzylamino)-methyl]-pentylamino}-1*H*-quinolin-4-one;
 10 2-{3-[1-(4,6-Dichloro-1*H*-indol-2-yl)-ethylamino]-propylamino}-1*H*-quinolin-4-one;
 2-{3-[(4-Methoxy-6-trifluoromethyl-1*H*-indol-2-ylmethyl)-amino]-propylamino}-1*H*-
 quinolin-4-one;
 2-{3-[(3-Cyano-1*H*-indol-7-ylmethyl)-amino]-propylamino}-1*H*-quinolin-4-one;
 2-{3-[(3-Bromo-5-methyl-1*H*-indol-7-ylmethyl)-amino]-propylamino}-1*H*-quinolin-4-one;
 15 2-{3-[(3-Bromo-5-methylsulfanyl-1*H*-indol-7-ylmethyl)-amino]-propylamino}-1*H*-
 quinolin-4-one;
 2-{3-[(3-Chloro-5-methylsulfanyl-1*H*-indol-7-ylmethyl)-amino]-propylamino}-1*H*-
 quinolin-4-one;
 2-{3-[(5-Chloro-3-methyl-1*H*-indol-7-ylmethyl)-amino]-propylamino}-1*H*-quinolin-4-one;
 20 2-(2-{[(4,6-Dichloro-1*H*-indol-2-ylmethyl)-amino]-methyl}-pentylamino)-1*H*-quinolin-4-
 one;
 2-[2-({1-(3,5-Dibromo-benzyl)-1*H*-indol-3-ylmethyl}-amino)-methyl]-pentylamino]-1*H*-
 quinolin-4-one;
 2-(3-{[1-(3,5-Dibromo-benzyl)-1*H*-indol-3-ylmethyl]-amino}-2-methyl-
 25 propylamino)-1*H*-quinolin-4-one;
 and 2-(3-{[4,6-Dichloro-3-(pyridin-4-yl)sulfanylmethyl]-1*H*-indol-2-ylmethyl}-amino)-
 propylamino)-1*H*-quinolin-4-one.

Most Preferred Compounds are:


- 30 2-{2-[(1-Benzyl-3-indolylmethylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
 2-[3-(4,6-Dichloro-2-indolylmethylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
 2-[3-(4-Chloro-3-trifluoromethyl-benzylamino)-propylamino]-1*H*-quinolin-4-one;
 2-{2-[(3-Trifluoromethylthiobenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;

2-[2-({[1-(3,5-Dibromo-benzyl)-1*H*-indol-3-ylmethyl]-amino}-methyl)-pentylamino]-1*H*-quinolin-4-one; and

2-[3-(4-Chloro-3-trifluoromethylbenzylamino)prop-1-ylamino]-1*H*-quinolin-4-one.

5 Compounds of Formula (I) may be prepared as outlined in the following scheme:

Scheme 1



10 Conditions: a) Dimethylsulfate, methylene chloride, acetone, reflux; b) trifluoroacetic anhydride, pyridine, rt; c) BocR₂NCH₂CHR₃CH₂NHR₄, acetonitrile, diisopropylethyl amine, reflux; d) concentrated hydrochloric acid, reflux; e) R₁CHO, acetic acid, methanol, rt, then sodium cyanoborohydride.

Methylation of 2,4-dihydroxyquinoline (1) with dimethylsulfate, followed by
 15 treatment with trifluoroacetic anhydride furnished intermediate 2, as outlined in Scheme 1 (see PCT application PCT/EP99/02648). Coupling of 2 with various mono-*tert*-butoxycarbonyl protected propylenediamines was accomplished in acetonitrile at reflux to give urethanes 3. Removal of the *tert*-butoxycarbonyl protecting group and conversion of the 4-methoxyquinoline to the corresponding quinolone with concentrated hydrochloric
 20 acid, followed by reductive alkylation of the resultant amines 4 with various aldehydes provided the target compounds 5.

In order to use a compound of the Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals it is normally formulated in
 25 accordance with standard pharmaceutical practice as a pharmaceutical composition.

Compounds of Formula (I) and their pharmaceutically acceptable salts may be administered in a standard manner for the treatment of the indicated diseases, for example orally, parenterally, sub-lingually, transdermally, rectally, via inhalation or via buccal administration.

- 5 Compounds of Formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as syrups, tablets, capsules and lozenges. A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or coloring agent. Where the composition is in the form of a tablet, any
10 pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, agar, pectin, acacia, stearic acid, starch, lactose and sucrose. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned
15 gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell.

- Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a
20 parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil, or sesame oil.

- Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.

- 25 A typical suppository formulation comprises a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogues.

- Typical transdermal formulations comprise a conventional aqueous or non-aqueous
30 vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.

Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to themselves a single dose.

Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg/Kg, and preferably from 1 mg to 100 mg/Kg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 100 mg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid. Each dosage unit for
5 intranasal administration contains suitably 1-400 mg and preferably 10 to 200 mg per person. A topical formulation contains suitably 0.01 to 1.0% of a compound of Formula (I).

The daily dosage regimen for oral administration is suitably about 0.01 mg/Kg to 40 mg/Kg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof
10 calculated as the free acid. The daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, of a compound of the Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for intranasal administration and oral inhalation is suitably about 10 to about 500 mg/person. The active ingredient may be administered from 1 to 6 times a day, sufficient
15 to exhibit the desired activity.

These 2-(NH- substituted) quinolones may be used for the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, restenosis, asthma, neurogenic inflammation and metabolic vasculopathies, addiction, schizophrenia, impulsivity, anxiety,
20 stress, depression, neuromuscular function, and diabetes.

No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.

The biological activity of the compounds of Formula (I) are demonstrated by the following tests:

25

Radioligand binding:

HEK-293 cell membranes containing stable cloned human and rat GPR-14 (20 ug/assay) were incubated with 200 pM [¹²⁵I] h-U-II (200 Ci/mmol⁻¹ in the presence of increasing concentrations of test compounds in DMSO (0.1 nM to 10 uM), in a final
30 incubation volume of 200 ul (20 mM Tris-HCl, 5 mM MgCl₂). Incubation was done for 30 minutes at room temperature followed by filtration GF/B filters with Brandel cell harvester. ¹²⁵I labeled U-II binding was quantitated by gamma counting. Nonspecific binding was defined by ¹²⁵I U-II binding in the presence of 100 nM of unlabeled human U-II. Analysis of the data was performed by nonlinear least square fitting.

Ca²⁺-mobilization:

A microtitre plate based Ca²⁺-mobilization FLIPR assay (Molecular Devices, Sunnyvale, CA) was used for the functional identification of the ligand activating HEK-293 cells expressing (stable) recombinant GPR-14. The day following transfection, cells were plated in a poly-D-lysine coated 96 well black/clear plates. After 18-24 hours the media was aspirated and Fluo 3AM-loaded cells were exposed to various concentrations (10 nM to 30 μ M) of test compounds followed by h-U-II. After initiation of the assay, fluorescence was read every second for one minute and then every 3 seconds for the following one minute.

10 The inhibitory concentration at 50% (IC₅₀) was calculated for various test compounds.

Inositol phosphates assays:

HEK-293-GPR14 cells in T150 flask were prelabeled overnight with 1 μ Ci myo-[³H] inositol per ml of inositol free Dulbecco's modified Eagle's medium. After labeling, the cells were washed twice with Dulbecco's phosphate-buffered saline (DPBS) and then incubated in DPBS containing 10 mM LiCl for 10 min at 37°C. The experiment was initiated by the addition of increasing concentrations of h-U-II (1 pM to 1 μ M) in the absence and presence of three different concentrations (0.3, 1 and 10 μ M) of test compounds and the incubation continued for an additional 5 min at 37°C after which the reaction was terminated by the addition of 10% (final concentration) trichloroacetic acid and centrifugation. The supernatants were neutralized with 100 μ l of 1M Trizma base and the inositol phosphates were separated on AG 1-X8 columns (0.8 ml packed, 100-200 mesh) in formate phase. Inositol monophosphate was eluted with 8 ml of 200 mM ammonium formate. Combined inositol di and tris phosphate was eluted with 4ml of 1M ammonium formate/ 0.1 M formic acid. Eluted fractions were counted in beta scintillation counter.

20 Based on shift from the control curve K_B was calculated.

Activity for the compounds of this invention range from 8 nM to 1 μ M.

The following examples are illustrative and are not limiting if the compounds of this invention.

30

EXAMPLES

Example 15 Preparation of 2-{3-[(1-Benzenesulfonyl-1*H*-indol-3-yl)methyl]-amino}-propylamino}-1*H*-quinolin-4-one

a) 2-Hydroxy-4-methoxyquinoline

10 A slurry of 2,4-dihydroxyquinoline (20.7 g, 0.13 mol), potassium carbonate (35.5 g, 0.26 mol), and dimethyl sulfate (14.6 ml, 0.15 mol) in acetone (800 ml) was heated at reflux for 3 days. The reaction was cooled to ambient temperature then evaporated under reduced pressure. The residue was slurried in a system of water (1000 ml) and ethyl acetate (500 ml) for 1 hour. The solids were collected then rinsed with water (3x250 ml) and ethyl ether (3x250 ml). Vacuum dried over phosphorus pentoxide to give 2-hydroxy-4-

15 methoxyquinoline (16.3 g, 72%) as tan powder. $M+CH_3CN = 217$.

b) 1,1,1-Trifluoromethanesulfonic acid 4-methoxyquinolin-2-yl ester

A slurry of 2-hydroxy-4-methoxyquinoline (13.4 g, 76.6 mmol) in pyridine (75 ml) was slowly treated under argon with trifluoromethanesulfonic anhydride (15.5 ml, 91.2 mmol). The reaction was allowed to stir at ambient temperature. After 4 days, the reaction was evaporated under reduced pressure to an oil that was dried by azeotrope with toluene (2x200 ml) to give the crude product as a brown solid. Flash chromatography on silica (1:1 ethyl acetate/hexanes as eluent) gave 1,1,1-trifluoromethanesulfonic acid 4-

20 methoxyquinolin-2-yl ester (20.4 g, 87%) as a yellow oil that solidified on standing.

25 $[M+H]^+ 308$, $M+CH_3CN = 349$.

c) [3-(4-Methoxyquinolin-2-ylamino)propyl]carbamic acid tert-butyl ester

A solution of 1,1,1-trifluoromethanesulfonic acid 4-methoxyquinolin-2-yl ester (4.51 g, 14.7 mmol), tert-butyl *N*-(3-aminopropyl)carbamate (3.07 g, 17.6 mmol), and diisopropylethylamine (3.84 ml, 22.0 mmol) in anhydrous acetonitrile (35 ml) was heated at reflux for 6 days. Cooled to ambient temperature then evaporated under reduced pressure to an oil. Taken into water (35 ml) then extracted into ethyl acetate. The extracts were dried (sodium sulfate) then concentrated to an oil. Column chromatography on silica (1:1 ethyl

30

acetate/hexanes) gave [3-(4-methoxyquinolin-2-ylamino)propyl]carbamic acid tert-butyl ester (3.10 g, 64%) as a colorless oil that solidified on standing. $[M+H]^+$ 332.

d) 3-(Aminoprop-1-ylamino)-1*H*-quinolin-4-one dihydrochloride

- 5 A solution of [3-(4-methoxyquinolin-2-ylamino)propyl]carbamic acid tert-butyl ester (650 mg, 2.0 mmol) in concentrated hydrochloric acid (35 ml) was heated at reflux for 24 hours, at which time it was allowed to cool to room temperature and evaporated under reduced pressure. The resultant oil was diluted with toluene and evaporated under reduced pressure to give 3-(aminoprop-1-ylamino)-1*H*-quinolin-4-one dihydrochloride (570 mg, 100%) as a white solid. $[M+H]^+$ 218.

e) 2-{3-[(1-Benzenesulfonyl-1*H*-indol-3-ylmethyl)-amino]-propylamino}-1*H*-quinolin-4-one

- 15 A solution of 3-(aminoprop-1-ylamino)-1*H*-quinolin-4-one dihydrochloride (240 mg, 0.83 mmol) and 1-benzenesulfonyl-3-indole carboxaldehyde (240 mg, 0.83 mmol) in methanol (40 ml) was treated with glacial acetic acid (20 drops) and sodium methoxide (95%, 89 mg, 1.7 mmol). The reaction stirred at ambient temperature for 24 hours then was treated with a solution of sodium cyanoborohydride (100 mg, 1.7 mmol) in methanol (2.0 ml). The reaction stirred at ambient temperature for 24 hours, at which time it was 20 evaporated under reduced pressure. The resultant residue was diluted with saturated aqueous sodium chloride (30 ml) and 10% aqueous sodium hydroxide (30 ml) and extracted with ethyl acetate (2x30 mL). The extracts were dried (sodium sulfate) and concentrated. Purification by reverse phase HPLC (water/acetonitrile, 9:1 to 1:9 gradient) gave 2-{3-[(1-Benzenesulfonyl-1*H*-indol-3-ylmethyl)-amino]-propylamino}-1*H*-quinolin-4-one (200 mg, 25 50%) as a white solid. $[M+H]^+$ 487.

Examples 2-9

Example	Compound	MS (ES+) m/e $[M+H]^+$
2	2-{3-[(1-Benzyl-1 <i>H</i> -indol-3-ylmethyl)-amino]-2-methyl-propylamino}-1 <i>H</i> -quinolin-4-one	451
3	2-{2-[(3-Phenoxy-benzylamino)-methyl]-pentylamino}-1 <i>H</i> -quinolin-4-one	442
	2-(3-{[1-(3,5-Dibromo-benzyl)-1 <i>H</i> -indol-3-ylmethyl]-	

4	amino}-2-methyl-propylamino)-1 <i>H</i> -quinolin-4-one	609
5	2-(2-([(4,6-Dichloro-1 <i>H</i> -indol-2-ylmethyl)-amino]-methyl)-pentylamino)-1 <i>H</i> -quinolin-4-one	457
6	2-[2-([(1-(3,5-Dibromo-benzyl)-1 <i>H</i> -indol-3-ylmethyl)-amino]-methyl)-pentylamino]-1 <i>H</i> -quinolin-4-one	635
7	2-{3-[(9 <i>H</i> -Xanthen-9-ylmethyl)-amino]-propylamino}-1 <i>H</i> -quinolin-4-one	412
8	2-(3-[(1-(1-Phenyl-methanoyl)-1 <i>H</i> -indol-3-ylmethyl)-amino]-propylamino)-1 <i>H</i> -quinolin-4-one	451

EXAMPLE 9

Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.

Inhalant Formulation

A compound of Formula I, (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.

10

<u>Tablets/Ingredients</u>	<u>Per Tablet</u>
1. Active ingredient (Cpd of Form. I)	40 mg
2. Corn Starch	20 mg
15 3. Alginic acid	20 mg
4. Sodium Alginate	20 mg
5. Mg stearate	<u>1.3 mg</u> 2.3 mg

20 Procedure for tablets:

Step 1 Blend ingredients No. 1, No. 2, No. 3 and No. 4 in a suitable mixer/blender.

Step 2 Add sufficient water portion-wise to the blend from Step 1 with careful mixing after each addition. Such additions of water and mixing until the mass is of a consistency to permit its conversion to wet granules.

- Step 3 The wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen.
- Step 4 The wet granules are then dried in an oven at 140°F (60°C) until dry.
- Step 5 The dry granules are lubricated with ingredient No. 5.
- 5 Step 6 The lubricated granules are compressed on a suitable tablet press.

Parenteral Formulation


- A pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of formula I in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then sterilized by filtration through a 0.22 micron membrane filter and sealed in sterile containers.
- 10

- The above specification and Examples fully disclose how to make and use the compounds of the present invention. However, the present invention is not limited to the particular embodiments described hereinabove, but includes all modifications thereof within the scope of the following claims. The various references to journals, patents and other publications which are cited herein comprise the state of the art and are incorporated herein by reference as though fully set forth.
- 15

20

What is claimed is:

1. A method of treating conditions associated with Urotensin-II imbalance by antagonizing the Urotensin-II receptor which comprises administering to a patient in need thereof, a compound of Formula I:



(I)

wherein:

- R₁ is phenyl, thienyl, benzothienyl, benzhydryl, xanthenyl, naphthyl, or indolyl, all of which may be substituted or unsubstituted by one or two substituents selected from: halogens, -CN, CH₃CO-, (C₁-6)alkyl, mono to perfluoro(C₁-3)alkyl, (C₂-6)alkenyl, (C₁-6)alkoxy, (C₅-10)aryloxy, phenyl(C₁-6)alkoxy, -OH, -NH₂, mono- or di-(C₁-6)alkylamino, -NO₂, -CO₂H, -CO₂(C₁-6)alkyl, -S(C₁-6)alkyl, -SO₂(C₁-6)alkyl, H₂NSO₂-, -CONH₂, -SO₂(C₅-10)aryl, or -CO₂N{(C₁-6)alkyl}₂; (add benzyl wording)
- R₂ is hydrogen or Me;
- R₃ is hydrogen, I, F, Br, Cl, C₁-6alkyl, C₁-6alkoxy, -OH, or -CN;
- X is -CH(R₄)- or CO;
- R₄ is hydrogen, $\epsilon\theta$, C₁-6 alkyl, or phenyl;
- Y is -CH₂C(R₅)(R₆)CH₂-;
- R₅ and R₆ are independently hydrogen or C₁-6 alkyl.

2. A method according to claim 1 wherein R₁ is substituted phenyl, thienyl, benzothienyl, benzhydryl, or indolyl; R₂ is hydrogen; R₃ is hydrogen, halo, or alkyl; X is CH₂; and Y is CH₂CR₅R₆CH₂, where R₅, and R₆ are hydrogen, or R₅ is hydrogen; and R₆ is n-propyl or methyl.

3. A method according to claim 2 wherein R₁ is 1-benzyl-3-indolyl, 4,6-dichloro-2-indolyl, 3-trifluoromethylthiophenyl, 2-fluoro-5-trifluoromethylphenyl, 4,6-dichloro-3-methyl-2-indolyl, 6-methoxy-4-trifluoromethyl-2-indolyl, 3,4-dichlorophenyl, 3,5-dibromophenyl, 4-chloro-3-trifluoromethylbenzyl or 3,5-Dibromobenzyl)-3-indolyl; R₂ is

hydrogen; R_3 is hydrogen, Cl, or Me; X is CH_2 ; and Y is $CH_2CR_5R_6CH_2$, wherein R_5 , and R_6 are H; or R_5 is hydrogen and R_6 is n-propyl, or methyl.

4. A method according to claim 1 wherein the compound is selected from:

- 5 2-{2-[(1-Benzyl-3-indolylmethylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 2-{2-[(3-Trifluoromethylthiobenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 2-{2-[(2-Fluoro-5-trifluoromethylbenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 2-{2-[(4-n-Butylbenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 2-{2-[(2,5-Dimethyl-1-phenyl-3-pyrrolylmethylamino)methyl]pent-1-ylamino}-1*H*-
- 10 quinolin-4-one;
- 2-{2-[(1-Bromo-2-naphthylmethylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 2-{2-[(4-Bromo-3,5-dimethoxybenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 2-{2-[(5-Bromo-2-fluorobenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one
- 2-{2-[(3-Iodobenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 15 2-{2-[(2,3-Difluoromethylenedioxybenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 2-{2-[(3-Fluoro-4-trifluoromethylbenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 2-{2-[(4,5-Dibromo-2-thienylmethylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 2-{2-[(2-Fluorenylmethylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 20 2-{2-[(3-Indolylmethylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 2-{2-[(1-Acetyl-3-indolylmethylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 2-{2-[(2-Chloro-3-trifluoromethylbenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 2-{2-[(2-Chloro-5-trifluoromethylbenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 2-{2-[(3,4-Dichlorobenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 25 2-{2-[(3,5-bis-Trifluoromethylbenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 2-{2-[(3,5-Dimethylbenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;
- 2-[3-(4,6-Dichloro-2-indolylmethylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
- 2-[3-(4,6-Dichloro-3-methyl-2-indolylmethylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
- 2-[3-(6-Methoxy-4-trifluoromethyl-2-indolylmethylamino)prop-1-ylamino]-1*H*-quinolin-4-
- 30 one;
- 2-[3-(3-Trifluoromethylthiobenzylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
- 2-[3-(3,4-Dichlorobenzylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
- 2-[3-(3,5-Dibromobenzylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
- 2-[3-(4,6-Dimethyl-2-indolylmethylamino)prop-1-ylamino]-1*H*-quinolin-4-one;

- 2-[3-(3,4-Dichlorobenzylamino)prop-1-ylamino]-6-methyl-1*H*-quinolin-4-one;
2-[3-(4,6-bis-Trifluoromethyl-2-indolylmethylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
2-[3-(3-Chlorobenzylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
2-[3-(4,5-Dibromo-2-thienylmethylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
5 2-[3-(3,4-Difluorobenzylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
2-[3-(1-Benzyl-3-indolylmethylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
2-[3-(2-Fluoro-5-trifluoromethylbenzylamino)prop-1-ylamino]-1*H*-quinolin-4-one;
2-[3-[(1-Benzyl-1*H*-indol-3-ylmethyl)-amino]-2-methyl-propylamino]-1*H*-quinolin-4-one;
2-[2-[(3-Phenoxy-benzylamino)-methyl]-pentylamino]-1*H*-quinolin-4-one;
10 2-[3-[(9*H*-Xanthen-9-ylmethyl)-amino]-propylamino]-1*H*-quinolin-4-one;
2-[3-[(1-Benzenesulfonyl-1*H*-indol-3-ylmethyl)-amino]-propylamino]-1*H*-quinolin-4-one;
2-[3-[(1-(1-Phenyl-methanoyl)-1*H*-indol-3-ylmethyl)-amino]-propylamino]-1*H*-quinolin-4-one;
2-[3-[(4-Bromo-5-ethyl-thiophen-2-ylmethyl)-amino]-propylamino]-1*H*-quinolin-4-one;
15 2-[3-[(6-Bromo-benzo[*b*]thiophen-2-ylmethyl)-amino]-propylamino]-1*H*-quinolin-4-one;
2-[3-[(4-Bromo-thiophen-2-ylmethyl)-amino]-propylamino]-1*H*-quinolin-4-one;
2-[3-(3,5-Dichloro-benzylamino)-propylamino]-1*H*-quinolin-4-one;
2-[3-(3-Iodo-benzylamino)-propylamino]-1*H*-quinolin-4-one;
2-[3-(4-Butyl-benzylamino)-propylamino]-1*H*-quinolin-4-one;
20 2-[3-(4-Chloro-3-trifluoromethyl-benzylamino)-propylamino]-1*H*-quinolin-4-one;
2-[2-[(2-Fluoro-4-trifluoromethyl-benzylamino)-methyl]-pentylamino]-1*H*-quinolin-4-one;
2-[2-[(4-Chloro-3-trifluoromethyl-benzylamino)-methyl]-pentylamino]-1*H*-quinolin-4-one;
2-[3-[1-(4,6-Dichloro-1*H*-indol-2-yl)-ethylamino]-propylamino]-1*H*-quinolin-4-one;
2-[3-[(4-Methoxy-6-trifluoromethyl-1*H*-indol-2-ylmethyl)-amino]-propylamino]-1*H*-
25 quinolin-4-one;
2-[3-[(3-Cyano-1*H*-indol-7-ylmethyl)-amino]-propylamino]-1*H*-quinolin-4-one;
2-[3-[(3-Bromo-5-methyl-1*H*-indol-7-ylmethyl)-amino]-propylamino]-1*H*-quinolin-4-one;
2-[3-[(3-Bromo-5-methylsulfanyl-1*H*-indol-7-ylmethyl)-amino]-propylamino]-1*H*-
quinolin-4-one;
30 2-[3-[(3-Chloro-5-methylsulfanyl-1*H*-indol-7-ylmethyl)-amino]-propylamino]-1*H*-
quinolin-4-one;
2-[3-[(5-Chloro-3-methyl-1*H*-indol-7-ylmethyl)-amino]-propylamino]-1*H*-quinolin-4-one;
2-[2-[(4,6-Dichloro-1*H*-indol-2-ylmethyl)-amino]-methyl]-pentylamino]-1*H*-quinolin-4-one;

2-[2-({[1-(3,5-Dibromo-benzyl)-1*H*-indol-3-ylmethyl]-amino}-methyl)-pentylamino]-1*H*-quinolin-4-one;

2-(3-({[1-(3,5-Dibromo-benzyl)-1*H*-indol-3-ylmethyl]-amino}-2-methyl-propylamino)-1*H*-quinolin-4-one;

- 5 and 2-(3-({[4,6-Dichloro-3-(pyridin-4-ylsulfanylmethyl)-1*H*-indol-2-ylmethyl]-amino}-propylamino)-1*H*-quinolin-4-one.

5. A method according to claim 1 wherein the compound is selected from:

2-{2-[(1-Benzyl-3-indolylmethylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;

- 10 2-[3-(4,6-Dichloro-2-indolylmethylamino)prop-1-ylamino]-1*H*-quinolin-4-one;

2-[3-(4-Chloro-3-trifluoromethyl-benzylamino)-propylamino]-1*H*-quinolin-4-one;

2-{2-[(3-Trifluoromethylthiobenzylamino)methyl]pent-1-ylamino}-1*H*-quinolin-4-one;

2-[2-({[1-(3,5-Dibromo-benzyl)-1*H*-indol-3-ylmethyl]-amino}-methyl)-pentylamino]-1*H*-quinolin-4-one; and

- 15 2-[3-(4-Chloro-3-trifluoromethylbenzylamino)prop-1-ylamino]-1*H*-quinolin-4-one.

6. A method according to Claim 1 wherein the disease is congestive heart failure, stroke, ischemic heart disease, angina, myocardial ischemia, cardiac arrhythmias, essential hypertension, pulmonary hypertension, COPD, restenosis, asthma, neurogenic inflammation
20 metabolic vasculopathies, addiction, schizophrenia, impulsivity, anxiety, stress, depression, neuromuscular function, or diabetes.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/47451

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/47

US CL : 514/312

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/312

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN Databases: Registry, Caplus, Medline, Biosis, USPatfull

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99/55677 (SMITHKLINE BEECHAM PLC) 4 November 1999, page 1, line 22-page 2, line 20.	1-6
A	US 6,075,137 (CULP et al.) 13 June 2000, col. 12, line 5-12	1-6



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

08 February 2002 (08.02.2002)

Date of mailing of the international search report

14 MAR 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Mimma Moezie, J.D.

Telephone No. (703) 308-1238